Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company advancing brain-targeted therapies through proprietary intranasal delivery technology, has announced a strategic collaboration with Receptor.AI to accelerate the development of new drug candidates for neurological conditions. The partnership will apply AI-based receptor modeling to optimize binding profiles for compounds acquired in 2023, supporting Oragenics' expansion beyond its lead candidate, ONP-002, in concussion. CEO Janet Huffman stated that the collaboration underscores the company's evolution into a diversified neurological therapeutics developer, combining artificial intelligence and precision delivery to streamline preclinical discovery and enhance capital efficiency.

The collaboration represents a significant step in Oragenics' strategic direction, moving beyond its primary focus on concussion treatment to address broader neurological conditions. By integrating Receptor.AI's advanced computational approaches with Oragenics' proprietary delivery platform, the companies aim to accelerate the identification and optimization of promising therapeutic candidates. This approach could potentially reduce traditional drug development timelines and costs while improving the precision of targeting neurological receptors. The partnership specifically targets compounds that Oragenics acquired last year, applying sophisticated AI modeling to enhance their therapeutic potential and binding characteristics.

Oragenics is working to revolutionize neurological care through its proprietary intranasal delivery technology, which has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. While the company's lead candidate, ONP-002, continues to advance with the goal of becoming the first FDA-approved treatment for concussion, this new collaboration expands the company's therapeutic pipeline. The platform technology holds potential for addressing neurodegenerative diseases, CNS disorders, and other neurological conditions beyond concussion. The latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN.

The full details of the partnership and additional information about the collaboration can be found in the complete press release available at https://ibn.fm/Wo8YZ. This strategic move positions Oragenics at the intersection of artificial intelligence and neurological drug development, potentially creating new pathways for treating complex brain disorders. The combination of AI-driven discovery with targeted delivery systems represents an innovative approach that could transform how neurological conditions are treated, offering hope for more effective and precisely targeted therapies for patients suffering from various brain-related disorders.